Ausgabe 2/2012
Inhalt (49 Artikel)
Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition
Linda Vidarsdottir, Gudridur Steingrimsdottir, Sigridur Klara Bodvarsdottir, Helga Margret Ogmundsdottir, Jorunn Erla Eyfjord
Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells
Eun-Taex Oh, Moon-Taek Park, Bo-Hwa Choi, Seonggu Ro, Eun-Kyung Choi, Seong-Yun Jeong, Heon Joo Park
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP
Nienke A. de Vries, Tessa Buckle, Jin Zhao, Jos H. Beijnen, Jan H. M. Schellens, Olaf van Tellingen
Putative mechanisms of antitumor activity of cyano-substituted heteroaryles in HeLa cells
Katja Ester, Fran Supek, Kristina Majsec, Marko Marjanović, David Lembo, Manuela Donalisio, Tomislav Šmuc, Ivana Jarak, Grace Karminski-Zamola, Marijeta Kralj
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents
Margaret E. Macy, Deborah DeRyckere, Lia Gore
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines
Martin Schmidt-Hieber, Robert Dabrowski, Andreas Weimann, Babette Aicher, Philipp Lohneis, Antonia Busse, Eckhard Thiel, Igor W. Blau
A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton
Jin Zhang, Jing Zhou, Xiaomei Ren, Yanyan Diao, Honglin Li, Hualiang Jiang, Ke Ding, Duanqing Pei
Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer
Lixin Ma, Haiquan Qiao, Changjun He, Qian Yang, Chun Hei Antonio Cheung, Jagat R. Kanwar, Xueying Sun
Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo
Sun-Young Han, Chong Ock Lee, Sung-Hoon Ahn, Mi-Ok Lee, So-Young Kang, Hyuk-Jin Cha, Sung Yun Cho, Jae Du Ha, Jae Wook Ryu, Heejung Jung, Hyoung Rae Kim, Jong Sung Koh, Jongkook Lee
The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates
AeRang Kim, Cindy McCully, Rafael Cruz, Diane E. Cole, Elizabeth Fox, Frank M. Balis, Brigitte C. Widemann
The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines
Miguel Muñoz, Ana González-Ortega, Rafael Coveñas
Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL
Rosario Yerbes, Abelardo López-Rivas
Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway
Chung Soo Lee, Eun-Ra Jang, Yun Jeong Kim, Soon Chul Myung, Wonyong Kim, Min Won Lee
The curcuminoid CLEFMA selectively induces cell death in H441 lung adenocarcinoma cells via oxidative stress
Kaustuv Sahoo, Mikhail G. Dozmorov, Shrikant Anant, Vibhudutta Awasthi
Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride
Kathryn A. Skelding, Richard D. Barry, Darren R. Shafren
Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms—action of two new agents
Rajeev Kumar, Vikas Verma, Amit Sarswat, J. P. Maikhuri, Ashish Jain, Rajeev K. Jain, V. L. Sharma, Diwakar Dalela, Gopal Gupta
New Vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential
Maria Teresa Conconi, Giovanni Marzaro, Adriano Guiotto, Luca Urbani, Ilenia Zanusso, Francesca Tonus, Mara Tommasini, Pier Paolo Parnigotto, Adriana Chilin
A phase I study of continuous infusion cilengitide in patients with solid tumors
Peter H. O’Donnell, Samir D. Undevia, Walter M. Stadler, Theodore M. Karrison, M. Kelly Nicholas, Linda Janisch, Mark J. Ratain
Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials
Stephane Ederhy, Christophe Massard, Ghislaine Dufaitre, Ratio Balheda, Catherine Meuleman, Carlos Gomez Rocca, Hassane Izzedine, Ariel Cohen, Jean-Charles Soria
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors
Laura Vidal, Margarita Magem, Clare Barlow, Beatriz Pardo, Amalia Florez, Ana Montes, Margarita Garcia, Ian Judson, Claudia Lebedinsky, Stan B. Kaye, Ramón Salazar
A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors
Bhuvaneswari Ramaswamy, Mitch A. Phelps, Robert Baiocchi, Tanios Bekaii-Saab, Wenjun Ni, Ju-Ping Lai, Anna Wolfson, Mark E. Lustberg, Lai Wei, Deidre Wilkins, Angela Campbell, Daria Arbogast, Austin Doyle, John C. Byrd, Michael R. Grever, Manisha H. Shah
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
Isamu Okamoto, Toshio Shimizu, Masaki Miyazaki, Junji Tsurutani, Yasuko Ichikawa, Masaki Terashima, Masayuki Takeda, Soichi Fumita, Emiko Ohki, Nobuyuki Kimura, Junichi Hashimoto, Kazuhiko Nakagawa
A phase I study of temsirolimus and metformin in advanced solid tumours
Mary J. MacKenzie, Scott Ernst, Craig Johnson, Eric Winquist
Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials
Nicolas Penel, Alain Duhamel, Antoine Adenis, Patrick Devos, Nicolas Isambert, Stéphanie Clisant, Jacques Bonneterre
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist
John W. Bauman, Joyce M. Antal, Laurel M. Adams, Brendan M. Johnson, Sharon C. Murray, Bin Peng, Lyndon C. Kirby, Peter F. Lebowitz, Thomas C. Marbury, Suzanne Swan, Maria Gutierrez
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy
Sang Joon Shin, Joong Bae Ahn, Kyung Soo Park, Yoon Jung Lee, Yong Sang Hong, Tae Won Kim, Hye Ryun Kim, Sun Young Rha, Jae Kyung Roh, Dal-Hyun Kim, Chin Kim, Hyun Cheol Chung
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
Katalin Boér, István Láng, Antonio Llombart-Cussac, Inger Andreasson, Guillermo L. Vivanco, Nick Sanders, Gillian M. Pover, Elizabeth Murray
Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study
Juan F. Cueva, Marcos Calvo, Urbano Anido, Luis León, Elena Gallardo, Carmen Areses, Beatriz Bernárdez, Lucía Gayoso, Jorge García, María Jesús Lamas, Teresa Curiel, Francisca Vázquez, Sonia Candamio, Yolanda Vidal, Francisco Javier Barón, Rafael López
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
Matthew D. Galsky, Daniel D. Von Hoff, Marcus Neubauer, Thomas Anderson, Mark Fleming, Yasir Nagarwala, Janine M. Mahoney, Dawn Midwinter, Linda Vocila, Tal Z. Zaks
Treatment of bevacizumab-induced hypertension by amlodipine
Olivier Mir, Romain Coriat, Stanislas Ropert, Laure Cabanes, Benoit Blanchet, Sandra Camps, Bertrand Billemont, Bertrand Knebelmann, François Goldwasser
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Suguru Mizuno, Keisuke Yamamoto, Hiroshi Yagioka, Yoko Yashima, Kazumichi Kawakubo, Hirofumi Kogure, Osamu Togawa, Saburo Matsubara, Yukiko Ito, Naoki Sasahira, Kenji Hirano, Takeshi Tsujino, Nobuo Toda, Minoru Tada, Masao Omata, Kazuhiko Koike
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response
Robert M. Rifkin, Andrew Greenspan, John F. Schwerkoske, Romeo A. Mandanas, Joe J. Stephenson, George T. Kannarkat, Feng Zhan, Kristi A. Boehm, Lina Asmar, Roy Beveridge
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study
Robert J. Morgan Jr, Lucille Leong, Warren Chow, David Gandara, Paul Frankel, Agustin Garcia, Heinz-Josef Lenz, James H. Doroshow
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
Luis Paz-Ares, Antonio López-Pousa, Andrés Poveda, Carmen Balañá, Eva Ciruelos, Joaquim Bellmunt, Javier García del Muro, Mariano Provencio, Antonio Casado, Fernando Rivera-Herrero, Miguel Ángel Izquierdo, Antonio Nieto, Adnan Tanović, Hernán Cortes-Funes, José María Buesa
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial
Tianhong Li, Scott D. Christensen, Paul H. Frankel, Kim A. Margolin, Sanjiv S. Agarwala, Thehang Luu, Philip C. Mack, Primo N. Lara Jr., David R. Gandara
Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
Ajjai Alva, Susan Slovin, Stephanie Daignault, Michael Carducci, Robert DiPaola, Ken Pienta, David Agus, Kathleen Cooney, Alice Chen, David C. Smith, Maha Hussain
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies
François Ghiringhelli, Julie Vincent, Boris Guiu, Bruno Chauffert, Sylvain Ladoire
Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib
Nathalie Lassau, Linda Chami, Serge Koscielny, Mohamed Chebil, Christophe Massard, Baya Benatsou, Sophie Bidault, Angela Cioffi, Jean-Yves Blay, Axel Le Cesne
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer
Stefan Madajewicz, David M. Waterhouse, Paul S. Ritch, M. Qaseem Khan, Donald J. Higby, Cynthia G. Leichman, Sandeep K. Malik, Patricia Hentschel, John F. Gill, Luping Zhao, Steven J. Nicol
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer
Daniel J. Renouf, Malcolm J. Moore, David Hedley, Sharlene Gill, Derek Jonker, Eric Chen, David Walde, Rakesh Goel, Bernadette Southwood, Isabelle Gauthier, Wendy Walsh, Lynn McIntosh, Lesley Seymour
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Kohei Shitara, Satoshi Yuki, Motoki Yoshida, Daisuke Takahari, Setsuo Utsunomiya, Tomoya Yokota, Yozo Sato, Yoshitaka Inaba, Masahiro Tajika, Hiroki Kawai, Hidekazu Yamaura, Mina Kato, Kentaro Yamazaki, Yoshito Komatsu, Kei Muro
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate
Justine Yang Bruce, Jens Eickhoff, Roberto Pili, Theodore Logan, Michael Carducci, Jamie Arnott, Anthony Treston, George Wilding, Glenn Liu
Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts
Paola Secchiero, Federica Corallini, Barbara Zavan, Claudio Tripodo, Vincenzo Vindigni, Giorgio Zauli
Perirenal hematoma associated with bevacizumab treatment
Hidetoshi Hayashi, Isamu Okamoto, Kazuhiko Nakagawa
The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL
Francesco Carinci, Lorenzo Monasta, Corrado Rubini, Daniela Stramazzotti, Annalisa Palmieri, Elisabetta Melloni, Alex Knowles, Luca Ronfani, Giorgio Zauli, Paola Secchiero
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients
Dok Hyun Yoon, Min-Hee Ryu, Baek-Yeol Ryoo, Moyeol Beck, Dae Ro Choi, Yoojin Cho, Jae-Lyun Lee, Heung-Moon Chang, Tae Won Kim, Yoon-Koo Kang
Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL
Arianna Gonelli, Oriano Radillo, Sara Drioli, Erika Rimondi, Paola Secchiero, Gian Maria Bonora
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model
Angelica Linnea Quartino, Lena E. Friberg, Mats O. Karlsson
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells
Cristina Oliveras-Ferraros, Anna Massaguer Vall-llovera, Dolors Carrion Salip, Alejandro Vazquez-Martin, Silvia Cufí, Bernardo Queralt, Begoña Martin-Castillo, Joan Brunet, Rafael de Llorens, Javier A. Menendez